Regeneron Pharmaceuticals Inc (REGN)

Payables turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cost of revenue (ttm)	US$ in thousands	3,224,100	3,108,900	3,035,000	2,928,200	2,840,300	1,931,200	1,870,100	1,713,600	1,562,500	2,368,000	2,272,300	2,331,400	2,287,000	1,801,000	1,644,200	1,437,900	1,399,600	1,706,700	1,803,300	1,876,000
Payables	US$ in thousands	789,500	497,300	561,700	671,300	606,600	536,600	547,300	599,500	589,200	—	—	—	564,000	—	—	—	475,500	—	—	—
Payables turnover		4.08	6.25	5.40	4.36	4.68	3.60	3.42	2.86	2.65	—	—	—	4.05	—	—	—	2.94	—	—	—

December 31, 2024 calculation

Payables turnover = Cost of revenue (ttm) ÷ Payables
= $3,224,100K ÷ $789,500K
= 4.08

The payables turnover ratio for Regeneron Pharmaceuticals Inc has varied over the analyzed periods. The payables turnover was not available for March, June, and September 2020.

From December 2020 to March 2022, the payables turnover fluctuated between 2.65 and 4.05, indicating that the company took around 2.65 to 4.05 times to pay off its suppliers' invoices within a given period.

Subsequently, from March 2023 to December 2024, the payables turnover improved steadily, reaching a peak of 6.25 in September 2024. This increase suggests that Regeneron Pharmaceuticals Inc enhanced its efficiency in paying off its accounts payable, settling its obligations with suppliers at a quicker rate.

Overall, an increasing trend in the payables turnover ratio indicates a more efficient management of payables and potentially healthier vendor relationships for the company. However, it's essential to consider industry benchmarks and compare this ratio with peers for a more comprehensive evaluation of Regeneron Pharmaceuticals Inc's payables management performance.